Sexual Effects of Transdermal or Vaginal Testosterone

Effects of Vaginal or Transdermal Testosterone on Sexual Response and Climacteric Symptoms in Postmenopausal Women

The aim of the study is to elucidate the role of testosterone treatment in postmenopausal women's sexual function and their therapeutic safety.

-General To evaluate the therapeutic efficacy of testosterone treatment in sexual dysfunction in postmenopausal patients.

-Specifics

1. To evaluate the prevalence of different sexual dysfunctions in postmenopausal patients, classifying them according to Diagnostic and Statistical Manual of Mental Disorders 5th (2013):

   • Female sexual desire / arousal disorder;
   • Female orgasm disorder;
   • pelvic or genital pain / penetration disorder;

2. To evaluate the response on climacteric symptoms after testosterone replacement using the Kupperman Menopausal Index;

Inclusion Criteria:

• Brazilian women with menopause time from 2 to 6 years;
• active sex life;
• absence of severe depression and anxiety, as evidenced by the Beck (depression specific) and Beck (anxiety specific) questionnaires;

Exclusion Criteria:

• disabling diseases;

• use of medicines that inhibit sexual desire;

• inability to answer the questionnaires;

• altered routine exams and comorbidities:

  • Severe hypertension with Blood Pressure measurement > 160 mmHg (maximum) or/and 90 mmHg (minimum) in two measurements
  • clinical or subclinical thyroid dysfunction: thyroid-stimulating hormone over 4
  • triglyceride dyslipidemia> 400
  • presence of occult blood in stool
  • hyperprolactinemia
  • fasting blood glucose> 100
  • presence of osteopenia or osteoporosis
  • BIRADS score greater than or equal to 3 on mammography
  • presence of endometrial echo> 4mm on transvaginal ultrasound
  • Presence of changes in oncotic colpocytology

• Diagnosis after psychological screening for moderate to severe anxiety / depression.